Orthofix Lowers 2026 Guidance, Withdraws Long-Term Targets Due to Medicare Reimbursement Cuts

summarizeSummary

Orthofix Medical Inc. has lowered its full-year 2026 financial guidance and withdrawn its long-term targets due to an expected 10% decline in Medicare reimbursement rates for its bone growth stimulators.

check_boxKey Events · Earnings and Guidance · OFIX

• Medicare Reimbursement Cut

  CMS updated billing requirements for non-invasive bone growth stimulators, leading to an expected 10% decline in average Medicare reimbursement for HCPCS codes E0747, E0748, and E0760, effective May 18, 2026.

• Lowered 2026 Financial Outlook

  The company now expects full-year 2026 net sales in the range of $838 million to $848 million and non-GAAP adjusted EBITDA between $90 million and $93 million, a reduction from previous expectations.

• No Positive Free Cash Flow Expected

  Orthofix Medical Inc. does not anticipate achieving positive free cash flow for the full-year 2026, exacerbating cash concerns previously noted in the Q1 2026 10-Q.

• Three-Year Targets Withdrawn

  The company's previously issued three-year financial targets are no longer applicable due to these developments, signaling increased long-term uncertainty.

auto_awesomeAnalysis · OFIX · Industrial Applications And Services

Orthofix Medical Inc. has significantly revised its financial outlook for 2026 and withdrawn its three-year financial targets. This follows a U.S. Food and Drug Administration reclassification of non-invasive bone growth stimulators and subsequent Centers for Medicare & Medicaid Services (CMS) updates, which are expected to reduce average Medicare reimbursement for these devices by approximately 10%. The lowered guidance for net sales and adjusted EBITDA, coupled with the expectation of no positive free cash flow for the full year, indicates a material negative impact on the company's profitability and liquidity, introducing considerable uncertainty for investors.